Advantages and problems with pregnancy registries: Observations and surprises throughout the life of the International lamotrigine pregnancy registry

Pharmacoepidemiology and Drug Safety

Volumn 23, Issue 8, 2014, Pages 779-786

  Sinclair, Susan ^a,b   Cunnington, Marianne ^c   Messenheimer, John ^d   Weil, John ^c   Cragan, Janet ^e   Lowensohn, Richard ^f   Yerby, Mark ^g   Tennis, Patricia ^h  

^a UNIVERSITY OF NORTH CAROLINA WILMINGTON   (United States)

^b SYNEOS HEALTH   (United States)

^c GLAXOSMITHKLINE   (United Kingdom)

^d GLAXOSMITHKLINE   (United States)

^e NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES   (United States)

^f OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^g North Pacific Neurological Research   (United States)

^h RTI INTERNATIONAL   (United States)

Author keywords

Birth defects; Lamotrigine; Methodology; Pharmacoepidemiology; Pregnancy; Registry

Indexed keywords

LAMOTRIGINE; ANTICONVULSIVE AGENT; TRIAZINE DERIVATIVE;

CHROMOSOME ABERRATION; CONGENITAL MALFORMATION; DISEASE REGISTRY; DRUG EXPOSURE; DRUG SAFETY; FEMALE; FOLLOW UP; GESTATIONAL AGE; HUMAN; MATERNAL AGE; PREGNANCY; PREGNANCY OUTCOME; PREVALENCE; PRIORITY JOURNAL; REVIEW; VOLUNTARY REPORTING; ABNORMALITIES, DRUG-INDUCED; INTERNATIONAL COOPERATION; PHARMACOEPIDEMIOLOGY; PROCEDURES; REGISTER; STANDARDS; STATISTICS AND NUMERICAL DATA;

ABNORMALITIES, DRUG-INDUCED; ANTICONVULSANTS; FEMALE; HUMANS; INTERNATIONAL COOPERATION; LOST TO FOLLOW-UP; PHARMACOEPIDEMIOLOGY; PREGNANCY; REGISTRIES; TRIAZINES;

EID: 84904981752     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3659     Document Type: Review

References (44)

1. United States Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Centers for Biologic Evaluation and Research. Guidance for industry. Establishing pregnancy exposure registries. Rockville, Maryland. August 2002. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM071639.pdf [18 April 2014].
2. European Medicines Agency. Guideline on the exposure to medicinal products during pregnancy; need for post-authorisation data. November 2005. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2009/11/WC500011303.pdf [18 April 2014].
3. Hirtz D, Thurman DJ, Gwinn-Hardy K, Mohamed M, Chaudhuri AR, Zalutsky R. How common are the "common" neurologic disorders? Neurology 2007; 68: 326-337.
4. Gaily E. Development and growth in children of epileptic mothers: a prospective controlled study. Acta Obstet Gynecol Scand 1991; 70(7-8): 631-632.
5. Holmes LB, Harvey EA, Coull BA, et al. The teratogenicity of anticonvulsant drugs. N Engl J Med 2001; 344: 1132-1138.
6. Battino D, Tomson T. Management of epilepsy during pregnancy. Drugs 2007; 67(18): 2727-2746.
7. Lander CM, Eadie MJ. Antiepileptic drug intake during pregnancy and malformed offspring. Epilepsy Res 1990; 7: 77-82.
8. Kallen B, Robert E, Mastroiacova P, Martinez-Frias ML, Castilla EE, Cocchi G. Anticonvulsant drugs and malformations: is there a drug specificity? Eur J Epidemiol 1989; 5: 31-36.
9. Oakeshott P, Hunt GM. Valproate and spina bifida. BMJ 1989; 298: 1300-1301.
10. Bertollini R, Kallen B, Mastrolacovo P, Robert E. Anticonvulsant drugs in monotherapy-effect on fetus. Eur J Epidemiol 1987; 3: 164-171.
11. Tennis P, Eldridge RR, International Lamotrigine Pregnancy Registry Scientific Advisory Committee. Preliminary results on pregnancy outcomes in women using lamotrigine. Epilepsia 2002; 43(10): 1161-1167.
12. The International Lamotrigine Pregnancy Registry Final Report. 1 September 1992 through 31 March 2010. Issued July 2010. Available at: http://pregnancyregistry.gsk.com/lamotrigine.html [18 April 2014].
13. Cunnington MC, Weil JG, Messenheimer JA, Ferber S, Yerby M, Tennis P. Final results from 18years of the International Lamotrigine Pregnancy Registry. Neurology 2011; 76(21): 1817-1823.
14. th Anniversary Edition Surveillance report: reporting birth defects surveillance data 1968-2003. Birth Defects Res (Part A) 2007; 79: 65-93.
15. Correa A, Cragan JD, Kucik JE, et al. Errata. Birth Defects Res (Part A) 2008; 82(1): 41-62.
16. Nelson K, Holmes LB. Malformations due to presumed spontaneous mutations in newborn infants. New Engl J Med 1989; 320: 19-23.
17. Holmes LB, Wyszynski DF. North American Anti-Epileptic Drug Pregnancy Registry. Epilepsia 2004; 45: 1465.
18. Holmes LB, Wyszynski DF, Baldwin EJ, Haebecker E, Glassman LH, Smith CR. Increased risk for nonsyndromic cleft palate among infants exposed to lamotrigine during pregnancy (abstract). Birth Defects Res A Clin Mol Teratol 2006; 76(5): 318.
19. Holmes LB, Baldwin EJ, Smith CR, et al. Increased frequency of isolated cleft palates in infants exposed to lamotrigine during pregnancy. Neurology 2008; 70: 2152-2158.
20. Holmes LB, Mittendorf R, Shen A, Smith CR, Hernandez-Diaz S. Fetal effects of anticonvulsant polytherapies: different risks from different drug combinations. Arch Neurol 2011; 68(10): 1275-1281.
21. UK Epilepsy and Pregnancy Register. Available at: www.epilepsyandpregnancy.co.uk/].
22. Morrow JI, Craig JJ, Russell AJC, et al. Which antiepileptic drugs are safest in pregnancy? Epilepsia 2003; 44(suppl 8): 60.
23. Morrow JI, Russell A, Gutherie E, et al. Malformation risks of anti-epileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psy 2006; 77: 193-198.
24. Samren EB, Van Dujjin CM, Christiaens GCML, Hoffman A, Lindout D. Antiepileptic drug regimens and major congenital abnormalities in the offspring. Ann Neurol 1999; 46: 739-746.
25. Centers for Disease Control and Prevention. Metropolitan Atlanta Congenital Defects Program 6-Digit code defect list. Available at: http://www.cdc.gov/ncbddd/birthdefects/documents/macdpcode0807.pdf [18 April 2014].
26. Correa-Villasenor A, Cragan J, Kucik J, O'Leary L, Siffel C, Williams L. The Metropolitan Atlanta Congenital Defects Program: 35years of birth defects surveillance at the Centers for Disease Control and Prevention. Birth Defects Res (Part A) 2003; 67: 617-624.
27. Antiretroviral Pregnancy Registry (APR) Steering Committee. Antiretroviral Pregnancy Registry International Interim Report for 1 January 1989 through 31 July 2013. Wilmington, NC: Registry Coordinating Center; 2013. Available at: http://APRegistry.com [18 April 2014].
28. Stone KM, Reiff-Eldridge R, White AD, et al. Pregnancy outcomes following systemic prenatal acyclovir exposure: conclusions from the International Acyclovir Pregnancy Registry, 1984-1999. Birth Defects Res (Part A) 2004; 70: 201-207.
29. Merck Pregnancy Registries. Pregnancy Registry for MAXALT. 2014, Available at: http://www.merckpregnancyregistries.com/maxalt.html [18 April 2014].
30. Roberts SS, Miller RK, Jones JK, et al. The Ribavirin Pregnancy Registry: findings after 5 years of enrollment, 2003-2009. Birth Defects Res A Clin Mol Teratol 2010; 88: 551-559.
31. Hirsch DK, Sinclair Roberts S, Brown VD, Palmer R, McLean J, Leclair D. The Savella® (Milnacipran) Pregnancy Registry: interim analysis and enrollment challenges. Birth Defects Res (Part A) 2013; 97(5): SI 299-299.
32. ClinicalTrials.gov. Cymbalta Pregnancy Registry. Available at: http://clinicaltrials.gov/ct2/show/NCT01074151 [18 April 2014].
33. MotHER Pregnancy Registry. Available at: http://herceptinpregnancyregistry.com/ [18 April 2014].
34. ClinicalTrials.gov. Multi-national Gilenya Pregnancy Registry. Available at: http://clinicaltrials.gov/show/NCT01285479 [18 April 2014].
35. ClinicalTrials.gov. Pregnancy exposure registry for Avonex. Available at: http://clinicaltrials.gov/ct2/show/NCT00168714 [18 April 2014].
36. Fleiss JL, Statistical Methods for Rates and Proportions (2nd edn). New York: Wiley. 1981. Print.
37. ClinicalTrials.gov. Map of pregnancy registries. Available at: http://clinicaltrials.gov/ct2/results/map?term=pregnancy+registry [18 April 2014].
38. European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) Electronic Register of Studies. Available at: http://www.encepp.eu/encepp/studiesDatabase.jsp [18 April 2014].
39. European Surveillance of Congenital Anomies (EUROCAT) Available at: http://www.eurocat-network.eu/ [18 April 2014].
40. Tomson T, Battino D, Bonizzoni E, et al. Collaborative EURAP Study Group. EURAP: an international registry of antiepileptic drugs and pregnancy. Epilepsia 2004; 45(11): 1463-1464.
41. International Registry of Antiepileptic Drugs and Pregnancy (EURAP). Interim Report November 2013. Available at: http://www.eurapinternational.org/registry/reports/index.php [13 April 2014].
42. Hernandez-Diaz S, Smith CR, Shen A, et al. Comparative safety of antiepileptic drugs during pregnancy. Neurology 2012; 78(21): 1692-1699.
43. Covington DL, Roberts SS, McKain LF. Lessons learned in conducting pregnancy exposure registries. Birth Defects Res (Part A) 2008; 82: 340.
44. Roberts S, Mallard A, Ferber S, Covington DL, Cunnington M. Does monetary compensation decrease losses to follow up in pregnancy exposure registries? Pharmacoepidemiology and Drug Safety 2007; 16(Supplement 2): S151.